Drugs / EBV mRNA vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07563023 | May 2026 → Dec 2027 expected | HIV-associated cancer | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05714748 | Feb 2023 → May 2025 overdue | cancer | West China Hospital | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07101536 | Aug 2025 → Dec 2026 expected | Epstein-Barr virus-related tumor | West China Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV mRNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07563023 ↗ |
| Modality | Messenger RNA (mRNA) | “EBV mRNA vaccine is a therapeutic vaccine based on messenger RNA (mRNA)” NCT07101536 ↗ |